Significantly improved aspartate aminotransferase (AST), NAFLD activity score (NAS), total cholesterol (TC), alanine aminotransferase (ALT), glutamine transferase (GGT), triglyceride (TG) levels, and insulin resistance index (HOMA-IR). Improved liver functions, hepatic fatty deposition, and glucose and lipids metabolism in NAFLD patients, enhancing the therapeutic effects. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.